STE up +1.60% percent right now. $STE High is at 63.56 and

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
STE up +1.60% percent right now. $STE High is at 63.56 and the Low 62.25 with current volume of 140,618.

Recent News posted below.

STE Steris Corp Recent Headline News

STERIS Has Returned 37.2% Since SmarTrend Recommendation (STE)
Comtex SmarTrend(R) - Mon Nov 10, 9:23AM CST
SmarTrend identified an Uptrend for STERIS (NYSE:STE) on February 18th, 2014 at $45.55. In approximately 9 months, STERIS has returned 37.24% as of today's recent price of $62.51.
STE: 63.41 (+0.99)

Steris
at Investor's Business Daily - Wed Nov 05, 5:48PM CST
Steris (STE) earnings rose 23.6% to 68 cents, topping by a nickel. Revenue increased 20.6% to $462.7 mil, above views for $452.5 mil. The company set full-year EPS outlook for $2.86-$2.91 vs. views for $2.88 a share. Shares rose 0.4% to 62.66.
STE: 63.41 (+0.99)

STERIS' CEO Walter Rosebrough on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 12:46PM CST

STE: 63.41 (+0.99)

Steris (STE) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 8:55AM CST

STE: 63.41 (+0.99)

Steris beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 2:21PM CST

STE: 63.41 (+0.99)

Stocks Turn Mixed; Epam Bounces Back
at Investor's Business Daily - Tue Nov 04, 2:13PM CST
Stocks continued to improve late Tuesday, turning mixed. The Dow Jones industrial average bounced back from a 0.5% loss and was up a fraction. The broader Nasdaq and the S&P 500 were off 0.4% each. They had been off 0.9% and 0.8%, respectively. NYSE...
FEYE: 32.13 (+1.51), AWAY: 29.44 (+0.23), FRGI: 56.69 (+1.10), SAVE: 78.75 (+1.44), LNKD: 229.49 (+6.45), SCTY: 51.76 (+0.79), STE: 63.41 (+0.99), PZZA: 50.03 (-0.05), JAZZ: 174.18 (+3.38), FL: 54.71 (+0.21), EPAM: 46.62 (-0.33)

Steris tops Street 2Q forecasts
Automated Insights - Tue Nov 04, 11:48AM CST
MENTOR, Ohio (AP) _ Steris Corp. (STE) on Tuesday reported earnings of $31 million in its fiscal second quarter.
STE: 63.41 (+0.99)

STERIS Corporation Announces Fiscal 2015 Second Quarter Results
Thomson Reuters ONE - Tue Nov 04, 10:30AM CST
- 21% Revenue Growth Fueled by Organic Growth and Acquisitions
STE: 63.41 (+0.99)

35.7% Return Seen to Date on SmarTrend STERIS Call (STE)
Comtex SmarTrend(R) - Fri Oct 31, 4:36PM CDT
SmarTrend identified an Uptrend for STERIS (NYSE:STE) on February 18th, 2014 at $45.55. In approximately 9 months, STERIS has returned 35.69% as of today's recent price of $61.80.
STE: 63.41 (+0.99)

DENTSPLY (XRAY) Beats Q3 Earnings, Misses on Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 3:30PM CDT
DENTSPLY International Inc. (XRAY) reported third-quarter 2014 adjusted earnings of 62 cents per share, which beat the Zacks Consensus Estimate by a couple of cents.
BRLI: 28.65 (-0.26), STE: 63.41 (+0.99), HSIC: 129.95 (+1.11), XRAY: 51.33 (+0.08)

STERIS Corporation to Announce Fiscal 2015 Second Quarter Financial Results on November 5, 2014
Thomson Reuters ONE - Tue Oct 28, 8:49AM CDT
Mentor, Ohio (October 28, 2014) - STERIS Corporation (NYSE: STE) today announced that it will release its fiscal 2015 second quarter financial results before the market opens on November 5, 2014, followed by a conference call at 10:00 a.m. Eastern Standard Time. The conference call can be heard live over the Internet at www.steris-ir.com or via phone by dialing 1- 800-369-8428 in the United States and Canada, or 1-773-799-3378 internationally, then referencing the password "STERIS".
STE: 63.41 (+0.99)

CONMED Q3 Earnings Rise but Revenues Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 2:10PM CDT
CONMED Corporation (CNMD) reiterated its adjusted earnings and revenue guidance for full-year 2014.
STE: 63.41 (+0.99), CNMD: 41.94 (+0.17), COO: 164.00 (-1.00)

STERIS Shares Up 31.5% Since SmarTrend's Buy Recommendation (STE)
Comtex SmarTrend(R) - Fri Oct 24, 10:57AM CDT
SmarTrend identified an Uptrend for STERIS (NYSE:STE) on February 18th, 2014 at $45.55. In approximately 8 months, STERIS has returned 31.53% as of today's recent price of $59.90.
STE: 63.41 (+0.99)

NYSE stocks posting largest percentage increases
AP - Thu Oct 23, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
CRS: 51.27 (-1.60), UFS: 40.82 (-0.08), CLV: 10.74 (-0.03), BBW: 17.74 (-0.04), CLF: 11.29 (+0.12), MTRN: 38.31 (-1.19), XRS: 32.92 (+0.73), GPI: 86.27 (-1.01), STE: 63.41 (+0.99), BRP: 23.33 (+0.04), TYL: 108.56 (-1.69), FUN: 46.97 (-0.73), UIS: 27.32 (+0.03), SIX: 39.89 (-0.16), TLLP: 57.00 (-0.73)

After Yesterday's Rally of 4.02% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Oct 22, 5:01PM CDT
STERIS (NYSE:STE) traded in a range yesterday that spanned from a low of $56.97 to a high of $59.21. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $56.87 on volume of 1.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
STE: 63.41 (+0.99)

Upgrade Alert for STERIS (STE)
Comtex SmarTrend(R) - Wed Oct 22, 6:55AM CDT
STERIS (NYSE:STE) was upgraded from Market Perform to Strong Buy at Raymond James today. The stock closed yesterday at $56.68 on volume of 484,000 shares, below average daily volume of 545,000. STERIS (NYSE:STE) has potential upside of 9.1% based on a current price of $56.68 and analysts' consensus price target of $61.83. The stock should find initial support at its 50-day moving average (MA) of $55.58 and further support at its 200-day MA of $51.36.
STE: 63.41 (+0.99)

Steris (STE) to Buy UK-based Synergy Health, Save Tax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 2:30PM CDT
Following this news, Steris' (STE) share price inched up 0.3% immediately, but eventually dropped 2.5% to close at $54.99 yesterday.
STE: 63.41 (+0.99), CAH: 78.93 (+0.66), XRAY: 51.33 (+0.08), COO: 164.00 (-1.00)

Lakeland Industries: Storm Warnings Ahead For Those Sailing On This LAKE
Looking For Diogenes - at Seeking Alpha - Wed Oct 15, 5:41AM CDT

STE: 63.41 (+0.99), APT: 3.27 (+0.01), LAKE: 13.10 (-0.19), CMN: 41.00 (+0.01)

Why STERIS (STE) Stock Is Gaining in Pre-Market Trading Today
at The Street - Mon Oct 13, 8:03AM CDT
STERIS (STE) stock is rising in pre-market trading after announcing it will purchase the U.K's Synergy Health for $1.9 billion in cash and stock.
STE: 63.41 (+0.99)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 235

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 41

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 127

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 147

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 68

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 113

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 22

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 253

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 112

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 0

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading
icles